

# EPZ005687

Catalog No: tcsc1215



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg



## Specifications

**CAS No:**

1396772-26-1

**Formula:**

$C_{32}H_{37}N_5O_3$

**Pathway:**

Epigenetics;Epigenetics

**Target:**

Histone Methyltransferase;Epigenetic Reader Domain

**Purity / Grade:**

>98%

**Solubility:**

DMSO : 9.4 mg/mL (17.42 mM; Need ultrasonic and warming)

**Observed Molecular Weight:**

539.67


## Product Description

EPZ005687 is a potent and selective inhibitor of **EZH2** with **K<sub>i</sub>** of 24 nM, and has 50-fold selectivity against EZH1 and 500-fold

selectivity against 15 other protein methyltransferases.

IC<sub>50</sub> & Target: Ki: 24 nM (EZH2)<sup>[1]</sup>

***In Vitro:*** EPZ005687 shows concentration-dependent inhibition of PRC2 enzymatic activity with an IC<sub>50</sub> value of 54±5 nM. EPZ005687 specifically inhibits H3K27 methylation in lymphoma cells. EPZ005687 has a notable effect on proliferation of the EZH2Y641F-bearing cell line. EPZ005687 decreases proliferation in mutant but not wild-type EZH2 lymphoma cells<sup>[1]</sup>. EPZ005687 (0.5, 1, 5 and 10 μM) induces an obvious apoptosis of U937 cells in a dose-dependent manner. EPZ005687 inhibits obviously the proliferation of U937 cells but has weak effect on the proliferation of NBMCD34<sup>+</sup> cells. EPZ005687 induces G1 phase blocking and decreases the percentage of cells in S phase in U937 cells. In addition, EPZ005687 produces obviously depletion of H3K27 methylation in U937 cells, but hardly has effect on the H3K27 methylation of NBMCD34<sup>+</sup> cells<sup>[2]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!